Results 61 to 70 of about 5,281 (177)

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

Arthritis Care &Research, Volume 78, Issue 3, Page 337-343, March 2026.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Moving urate-lowering therapy in gout beyond guideline recommendations

Seminars in Arthritis and Rheumatism
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. An alternative "treat-to-avoid-symptoms" in gout has been suggested, albeit without a clear definition of what this means and how it might be implemented in clinical trials or clinical practice ...
Lisa K Stamp, Nicola Dalbeth
openaire   +2 more sources

Atomically Precise Clusterzymes: A Programmable Optoelectronic Platform for Neuroscience

Advanced Science, Volume 13, Issue 16, 18 March 2026.
Atomically precise clusterzymes, engineered via atomic and ligand design, serve as programmable platforms for neuroscience applications. They demonstrate tailored biocatalysis for neuroinflammation, tunable optical properties for deep‐tissue bioimaging and 3D visualization, and enhanced charge transfer for brain–computer interfaces.
Si Sun, Di Liu, Sufei Zhou, Yang Wang, Hao Wang, Ziliang Zheng, Xiao‐Dong Zhang   +6 more
wiley   +1 more source

Current issues in the practical use of allopurinol in patients with gout and hyperuricemia

Современная ревматология
The cornerstone of the treatment of gout and hyperuricemia (HU) is the use of urate-lowering drugs, primarily xanthine oxidase inhibitors. Allopurinol, which has been used to treat gout for six decades, is the first line urate-lowering therapy (ULT ...
M. S. Eliseev
doaj   +1 more source

The genetics of gout: towards personalised medicine?

BMC Medicine, 2017
Over the last decade, there have been major advances in the understanding of the genetic basis of hyperuricaemia and gout as well as of the pharmacogenetics of urate-lowering therapy.
Nicola Dalbeth, Lisa K. Stamp, Tony R. Merriman   +2 more
doaj   +1 more source

Development of a multivariable improvement measure for gout

Arthritis Research & Therapy, 2020
Background Gout is a heterogeneous inflammatory disease with numerous clinical manifestations. A composite means to assess the impact of therapy on numerous aspects of gout could be useful.
Naomi Schlesinger, N. Lawrence Edwards, Anthony E. Yeo, Peter E. Lipsky   +3 more
doaj   +1 more source

Daidzein Ameliorate Hyperuricemia by Upregulating ABCG2 Expression via Activation of PPARγ and PI3K/AKT Pathways

Food Frontiers, Volume 7, Issue 2, March 2026.
Hyperuricaemia is a chronic metabolic disorder arising from impaired purine metabolism, exhibiting marked gender disparities in its prevalence. Daidzein, possessing oestrogen‐like effects, promotes uric acid excretion and improves hepatic and renal function, thereby presenting potential utility as an adjunctive therapeutic agent for hyperuricaemia ...
Zicheng Zhu, Jujie Pan, Ruixia Bao, Beibei Chen, Siyi Li, Ziyu Che, Qian Chen, Yuzheng Wu, Dan Wang, Tao Wang   +9 more
wiley   +1 more source

Uricases: reflections on recent developments in the management of challenging gout patients [PDF]

Exploration of Musculoskeletal Diseases
Oral urate-lowering therapy (ULT) is key to treating gout. However, many patients receiving oral ULT do not achieve the target serum urate (SU) levels, partly because some patients cannot tolerate or have contraindications to their use, mainly due to ...
Naomi Schlesinger, Dan Kaufmann
doaj   +1 more source

Clinical Outcomes and Management in Late Diagnosed Siblings Affected With Attenuated GSD Ib

JIMD Reports, Volume 67, Issue 2, March 2026.
ABSTRACT Glycogen storage disease 1b (GSD1b) typically presents in early infancy with poor fasting tolerance, hepatomegaly, and neutropenia. We report two siblings who were diagnosed with GSD1b in adulthood. Both had a normal fasting tolerance throughout childhood and, as adults, were able to fast for at least 16 h without developing hypoglycaemia. The
Gregory Lynch, Alison Woodall, Charlotte Dawson, Philip Newsome, Maria Veiga‐da‐Cunha, Karolina M. Stepien   +5 more
wiley   +1 more source

Kiesselbach’s area nasal septal gouty tophus with an integrated “3 + 2” diagnostic algorithm: a case report

Journal of Medical Case Reports
Background Gout, characterized by monosodium urate crystal deposition, rarely involves the nasal septum, with only a few reported cases. Such unusual presentations can mimic other conditions, necessitating prompt and accurate diagnosis.
Weikun Chen, Wanling Chen, Duanyue Guo, Ziyue Wang, Ziwen Shi, Junwei Zhong   +5 more
doaj   +1 more source